FutraMed, Inc.

medical devices

About

FutraMed, Inc. is a medical technology company addressing the opioid crisis with the Limoge TCES—a non-invasive, handheld neuromodulation device designed to manage Opioid Use Disorder (OUD) across both acute and long-term phases. Backed by prior European regulatory approval and built for ease of use in clinical or rural settings, the Limoge TCES safely alleviates withdrawal symptoms and supports sustained recovery by enhancing neuroplasticity and emotional resilience. We are currently pursuing FDA clearance and seeking strategic partners and early investors to help bring this transformative technology to detox centers, rehab programs, and underserved communities across the U.S.

Technologies

Gmail Google Apps DigitalOcean WordPress.org Nginx Bootstrap Framework Mobile Friendly Google Analytics ShareThis Node.js Android Remote AI IoT

Keywords

medical equipment manufacturing opioid withdrawal syndrome battery-powered device electrical stimulation drug potentiation regulatory approval opioid reduction healthcare technology medical device tces b2b substance abuse electrical current therapy healthcare electrical cranial stimulation drug withdrawal ce mark certification low-cost device analgesic effect clinical benefits limoge tces device non-invasive neurostimulation addiction recovery technology electroanesthesia medical innovation fda regulatory pathway services transcutaneous cranial electrical stimulation biotechnology biophysical therapy

Location

9690 S 300 W, Sandy, Utah, United States, 84070

Related Companies

Companies in the same industry